Keyphrases
Doxorubicin
77%
Soft Tissue Sarcoma
66%
Chemotherapy
44%
Metastatic Soft Tissue Sarcoma
44%
Prognostic Factors
44%
Overall Survival
28%
Randomized Phase III Trial
26%
Denmark
25%
Cancer Treatment
25%
European Organizations
25%
Locally Advanced Unresectable
23%
Docetaxel
22%
Belinostat
22%
Appendicular
22%
Gynecologic Oncology Group
22%
Single Institution
22%
Delayed Diagnosis
22%
Functional Outcome
22%
Malignant Paraganglioma
22%
Quality of Life
22%
Predictive Factors
22%
Malignant Pheochromocytoma
22%
Functional Quality
22%
Gemcitabine
22%
Adult Patients
22%
Osteosarcoma
22%
Bone Sarcoma
22%
Limb-sparing Surgery
22%
Ifosfamide
22%
Phase III Clinical Trial
22%
Survival Factor
22%
Group Studies
22%
Trabectedin
22%
Metastatic Sarcoma
22%
Retrospective Analysis
22%
Large Series
22%
Medicine and Dentistry
Doxorubicin
100%
Soft Tissue Sarcoma
91%
Prognostic Factor
59%
Osteosarcoma
44%
Neoplasm
38%
Diseases
38%
Overall Survival
37%
Leiomyosarcoma
27%
Clinical Trial
25%
Oncology
23%
Connective Tissue Cancer
23%
Docetaxel
22%
Belinostat
22%
Hyponatremia
22%
Gemcitabine
22%
Isoprenaline
22%
Pheochromocytoma
22%
Predictive Factor
22%
Cancer Treatment
22%
Gynecological Oncology
22%
Arm
22%
Somatostatin Derivative
16%
Cancer
16%
Pharmacology, Toxicology and Pharmaceutical Science
Doxorubicin
77%
Soft Tissue Sarcoma
66%
Chemotherapy
44%
Ifosfamide
44%
Leiomyosarcoma
27%
Malignant Neoplasm
27%
Gemcitabine
22%
Docetaxel
22%
Trabectedin
22%
Osteosarcoma
22%
Overall Survival
22%
Diseases
18%